GlassScriptPhysician profile
Aruna Narasimmam
NPI 1518964733
$6,120.59
in general payments reported to CMS, 2019-2025
41 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $610 · 2021: $900 · 2022: $1,165 · 2023: $1,328 · 2024: $1,225 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $997.33 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $657.25 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $550.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $503.92 | 2021-2024 | |
| Amgen INC. | $498.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $484.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $249.29 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.51 | 2021-2025 | |
| Daiichi Sankyo INC. | $212.24 | 2019-2025 | Injectafer |
| Abbott Laboratories | $188.13 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $167.39 | 2019-2024 | Welireg, Keytruda |
| Astrazeneca Pharmaceuticals LP | $146.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.09 | 2019-2024 | Jardiance, Tradjenta |
| Vanda Pharmaceuticals INC. | $114.36 | 2022-2023 | Hetlioz |
| Philips North America LLC | $108.06 | 2023-2025 | (Ck7) Extended Holter, Extended Holter, Event |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Narasimmam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.